Cancer Immunotherapy Market Research Till 2023-Top Key Players Bristol-Myers Squibb, F. Hoffmann-LA Roche Ltd, GlaxoSmithKline, Pfizer, Eli Lilly and Company,Among Others

According to Research for Markets, the Global Cancer Immunotherapy market is estimated at $62.57 billion in 2016 and is expected to reach $160.24 billion by 2023 growing at a CAGR of 14.3% from 2016 to 2023. Rapid increase in cases of cancer across the globe, technical advancement in treatment therapies, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment and lack of awareness are the restraints hampering the market. On the other hand rise in clinical trials against different cancers in immunotherapy and elevated expansion prediction in developing countries are some opportunities for the market over the forecast period.

Looking for more information on this market? Request for Free Sample Copy of Report @ http://www.researchformarkets.com/sample/cancer-immunotherapy-global-market-5208

Based on product, the monoclonal antibodies are made by single clone of cells or cell line and are comprised of identical antibody molecules. The factors such as growing occurrence of cancer and other chronic diseases, rising awareness among patients and rising requirement for personalized medicine are favoring this product’s segment.

In terms of geography, North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the Cancer Immunotherapy Market include Bristol-Myers Squibb, F. Hoffmann-LA Roche Ltd, GlaxoSmithKline, Pfizer, Eli Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Amgen Inc., Biovest International Inc, Ablynx NV, Genentech Inc, Bellicum Pharmaceuticals Inc, Bayer AG, Oxford BioTherapeutics Ltd., Merck, Sydys Corporation, Dendreon, Xencor, Daiichi Sankyo and TG Therapeutics.

Product Types Covered:

• Immune Checkpoint Inhibitors
o Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
o Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
• Cancer Monoclonal Antibodies
o Conjugated Monoclonal Antibodies
o Bispecific Monoclonal Antibodies
o Naked Monoclonal Antibodies
• Immunomodulators
o Oncolytic Virus
o Interleukins (IL)
o Interferons (IFN)
• Cancer Vaccines
o Prophylactic Vaccines
o Therapeutic Vaccines
• Cell Therapies
o Chimeric Antigen Receptor (CAR) T Cell Therapy
o Dendritic Cells

Cancer Types Covered:

• Breast Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Multiple Myeloma
• Melanoma
• Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Other Cancer Types

End Users Covered:

• Hospital
• Clinics
• Other End Users

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Get Instant Discount on This Report @ www.researchformarkets.com/discount/cancer-immunotherapy-global-market-5208

Short review On Table Of Content-

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Immunotherapy Market, By Product Type
5.1 Introduction
5.2 Immune Checkpoint Inhibitors
5.2.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
5.2.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
5.3 Cancer Monoclonal Antibodies
5.3.1 Conjugated Monoclonal Antibodies
5.3.2 Bispecific Monoclonal Antibodies
5.3.3 Naked Monoclonal Antibodies
5.4 Immunomodulators
5.4.1 Oncolytic Virus
5.4.1.1 Immunity as an Obstacle
5.4.1.2 Immunotherapy
5.4.1.3 Approved Products & Clinical Trails
5.4.1.4 Immunity as an Ally
5.4.2 Interleukins (IL)
5.4.3 Interferons (IFN)
5.5 Cancer Vaccines
5.5.1 Prophylactic Vaccines
5.5.2 Therapeutic Vaccines
5.6 Cell Therapies
5.6.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
5.6.2 Dendritic Cells

6 Global Cancer Immunotherapy market, By Cancer Type
6.1 Introduction
6.2 Breast Cancer
6.3 Colorectal Cancer
6.4 Head & Neck Cancer
6.5 Multiple Myeloma
6.6 Melanoma
6.7 Lung Cancer
6.8 Prostate Cancer
6.9 Ovarian Cancer
6.10 Pancreatic Cancer
6.11 Other Cancer Types

7 Global Cancer Immunotherapy market, By End User
7.1 Introduction
7.2 Hospital
7.3 Clinics
7.4 Other End Users

8 Global Cancer Immunotherapy Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Bristol-Myers Squibb
10.2 F. Hoffmann-LA Roche Ltd
10.3 GlaxoSmithKline
10.4 Pfizer
10.5 Eli Lilly and Company
10.6 Janssen Global Services, LLC (Johnson and Johnson)
10.7 Novartis
10.8 Amgen Inc.
10.9 Biovest International Inc
10.10 Ablynx NV
10.11 Genentech Inc
10.12 Bellicum Pharmaceuticals Inc
10.13 Bayer AG
10.14 Oxford BioTherapeutics Ltd.
10.15 Merck
10.16 Sydys Corporation
10.17 Dendreon
10.18 Xencor
10.19 Daiichi Sankyo
10.20 TG Therapeutics

If you have any special requirements, please let us know and we will offer you the report as you want.

Know More About our Knowledge store @ http://www.researchformarkets.com/reports/cancer-immunotherapy-global-market-5208

About Us:

Research For Markets indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. We have established the pillars of our flourishing institute on the grounds of Credibility and Reliability. RFM delve into the markets across Asia Pacific, North America, South America, Europe, Middle East And Africa.

Contact Us:

Mr. A Naidu

Research for Markets

Email: alan.naidu@researchformarkets.com

+44 8000-4182-37

This release was published on openPR.